Mirdametinib for NF1 skin bumps
Treatments studied
Part of Cancer, Genetic & congenital, Skin clinical trials.
This study tests an oral drug called mirdametinib to see if it can shrink skin bumps caused by NF1. If you have at least 24 of these bumps on your skin and are in decent health, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 or older and have a confirmed diagnosis of neurofibromatosis type 1 (NF1).
- You need at least 24 measurable skin bumps (called cutaneous neurofibromas), with at least 6 of them on your back.
- You should be in generally good health, able to do most daily tasks without much help (Karnofsky score 80% or higher).
- You must have normal kidney and liver function, and adequate blood counts (check with your doctor).
- If you are a woman who could become pregnant, you must not be pregnant or nursing and must use effective birth control. Men must also use condoms and not donate sperm during the study and for a while after.
- You cannot have taken a MEK inhibitor drug in the past year or had to stop one due to side effects, and you cannot have certain heart, eye, or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called IMLYGIC (talimogene laherparepvec) to see if it is safe and tolerable for treating skin bumps (cutaneous neurofibromas) in adults with NF1. The drug is injected directly into the bumps, and the study will check if it can shrink them or improve symptoms.
This trial tests a drug called mirdametinib for people with specific types of brain tumors or neurohistiocytosis (a rare condition affecting the nervous system). The drug targets mutations that cause these conditions to grow.
This trial studies whether the medicine abemaciclib can shrink or slow the growth of “atypical neurofibromas” in people with NF1. Participants take pills and undergo regular check-ups, including MRI scans to measure the tumor.
This trial tests two targeted drugs (selumetinib and milademetan) for people with neurofibromatosis type 1 (NF1) who have either a malignant peripheral nerve sheath tumor (MPNST) or an atypical neurofibromatous neoplasm with uncertain biologic potential (ANNUBP). The goal is to see if blocking certain proteins can shrink or control these tumors.
This study tracks people with NF1 to watch for when benign nerve tumors turn cancerous. It uses regular MRI scans to catch changes early, which could help guide treatment decisions.
This study talks with people who have NF1 (and caregivers of children with NF1) about how visible tumors affect them. The goal is to create questionnaires that measure these concerns, which could lead to better support and treatments.
Hear when a new NF1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.